JP6494507B2 - グリピカン−３に対する高親和性モノクローナル抗体およびその使用 - Google Patents

グリピカン−３に対する高親和性モノクローナル抗体およびその使用 Download PDF

Info

Publication number
JP6494507B2
JP6494507B2 JP2015515243A JP2015515243A JP6494507B2 JP 6494507 B2 JP6494507 B2 JP 6494507B2 JP 2015515243 A JP2015515243 A JP 2015515243A JP 2015515243 A JP2015515243 A JP 2015515243A JP 6494507 B2 JP6494507 B2 JP 6494507B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
gpc3
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015515243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526387A (ja
JP2015526387A5 (enExample
Inventor
ミッチェル ホー，
ミッチェル ホー，
イェン ティー． フォン，
イェン ティー． フォン，
ウェイ ガオ，
ウェイ ガオ，
イーファン ジャン，
イーファン ジャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2015526387A publication Critical patent/JP2015526387A/ja
Publication of JP2015526387A5 publication Critical patent/JP2015526387A5/ja
Application granted granted Critical
Publication of JP6494507B2 publication Critical patent/JP6494507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
JP2015515243A 2012-06-01 2013-05-31 グリピカン−３に対する高親和性モノクローナル抗体およびその使用 Active JP6494507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654232P 2012-06-01 2012-06-01
US61/654,232 2012-06-01
PCT/US2013/043633 WO2013181543A1 (en) 2012-06-01 2013-05-31 High-affinity monoclonal antibodies to glypican-3 and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019000195A Division JP2019062910A (ja) 2012-06-01 2019-01-04 グリピカン−３に対する高親和性モノクローナル抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2015526387A JP2015526387A (ja) 2015-09-10
JP2015526387A5 JP2015526387A5 (enExample) 2016-06-02
JP6494507B2 true JP6494507B2 (ja) 2019-04-03

Family

ID=48699931

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015515243A Active JP6494507B2 (ja) 2012-06-01 2013-05-31 グリピカン−３に対する高親和性モノクローナル抗体およびその使用
JP2019000195A Pending JP2019062910A (ja) 2012-06-01 2019-01-04 グリピカン−３に対する高親和性モノクローナル抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019000195A Pending JP2019062910A (ja) 2012-06-01 2019-01-04 グリピカン−３に対する高親和性モノクローナル抗体およびその使用

Country Status (6)

Country Link
US (1) US9409994B2 (enExample)
JP (2) JP6494507B2 (enExample)
KR (1) KR102159773B1 (enExample)
CN (1) CN104520331B (enExample)
SG (1) SG11201407972RA (enExample)
WO (1) WO2013181543A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
TR201815863T4 (tr) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
CN105849562B (zh) * 2013-12-24 2019-08-16 中外制药株式会社 可溶性gpc3蛋白质的测定方法
CN113933504A (zh) 2014-05-08 2022-01-14 中外制药株式会社 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR102739664B1 (ko) * 2015-04-20 2024-12-05 미노믹 인터내셔널 리미티드 치료용 항체 및 이의 용도
EP3318879B1 (en) 2015-07-01 2020-10-21 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
WO2017154839A1 (ja) * 2016-03-10 2017-09-14 国立研究開発法人国立がん研究センター 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
MX2018010988A (es) * 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO2017196847A1 (en) * 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
CA3049189A1 (en) 2017-01-10 2018-07-19 Yamaguchi University Anti-gpc3 antibody
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
SG11201909728XA (en) 2017-04-26 2019-11-28 Eureka Therapeutics Inc Constructs specifically recognizing glypican 3 and uses thereof
CN108250266A (zh) * 2017-09-05 2018-07-06 首都医科大学附属北京佑安医院 一种hla-a11限制性gpc3源性多肽及包含它的疫苗
WO2019094482A1 (en) 2017-11-10 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting tumor antigens
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CN110577600B (zh) * 2018-06-07 2021-05-04 中国科学院上海药物研究所 靶向gpc3的抗体-药物偶联物及其制备方法和用途
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN109021108B (zh) * 2018-08-27 2019-06-25 南京医科大学 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
CN113784987B (zh) * 2019-01-22 2024-09-13 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
CN120118189A (zh) * 2019-03-21 2025-06-10 新加坡科技研究局 针对磷脂酰肌醇蛋白聚糖-3的人单克隆抗体
US12466891B2 (en) 2019-05-15 2025-11-11 Kyowa Kirin Co., Ltd. Bispecific antibody binding to CD40 and GPC3
CA3141614A1 (en) * 2019-05-24 2020-12-03 Memorial Sloan Kettering Cancer Center Anti-glypican-3 antibodies and uses thereof
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
CN112390886B (zh) * 2019-08-16 2022-08-16 原启生物科技(上海)有限责任公司 一种分离的抗原结合蛋白及其用途
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN115087466A (zh) * 2019-12-12 2022-09-20 森迪生物科学公司 用于细胞的调控装甲的方法和组合物
EP4110912A4 (en) * 2020-02-27 2024-07-10 Legend Biotech Ireland Limited ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND METHODS OF USE THEREOF
CN111662385B (zh) * 2020-04-08 2022-11-22 重庆金迈博生物科技有限公司 全人源抗人gpc3单克隆抗体及其用途
CN111187351B (zh) * 2020-04-14 2020-08-04 浙江恒驭生物科技有限公司 一种肝癌检测试剂盒
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
CN111349178B (zh) * 2020-05-25 2020-09-29 北京达熙生物科技有限公司 一种靶向gpc3的嵌合抗原受体(car)及其抗癌的用途
CN120383678A (zh) * 2020-10-23 2025-07-29 华中农业大学 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用
CN114478779B (zh) * 2020-10-26 2024-10-11 华中农业大学 人源化的磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CN114685668B (zh) * 2020-12-28 2023-10-13 石药集团巨石生物制药有限公司 一种人gpc3单克隆抗体及其缀合物
CN117083301A (zh) * 2021-02-03 2023-11-17 先声再明医药有限公司 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
CN113072643B (zh) * 2021-03-22 2021-10-15 南京医科大学 抗Glypican-3耐酸性全人源抗体、其免疫毒素、其嵌合抗原受体细胞及应用
CN117730100A (zh) * 2021-06-08 2024-03-19 凯德药业股份有限公司 Gpc3结合分子
WO2023283361A1 (en) * 2021-07-07 2023-01-12 Triumvira Immunologics Usa, Inc. Gpc3 t cell-antigen couplers and uses thereof
US20240368303A1 (en) * 2021-09-24 2024-11-07 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against gpc3 and uses thereof
WO2023056474A1 (en) * 2021-09-30 2023-04-06 University Of Washington Mouse anti-human monoclonal antibody against glypican-3
WO2024061305A1 (zh) * 2022-09-22 2024-03-28 上海美雅珂生物技术有限责任公司 Gpc3抗体药物偶联物及其应用
CN120225568A (zh) * 2022-12-27 2025-06-27 广州瑞风生物科技有限公司 一种融合蛋白及其应用
CN117304343B (zh) * 2023-10-11 2024-05-07 北京景达生物科技有限公司 Gpc3靶向的car-nk细胞的制备及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DK0531434T3 (da) 1990-05-11 2000-01-31 Us Health Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
DE69333951D1 (de) 1992-06-18 2006-02-02 Us Gov Health & Human Serv Rekombinantes pseudomonas exotoxin mit gesteigerter aktivität
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6296843B1 (en) 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
EP1180123B1 (en) 1999-05-27 2008-07-16 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
DK2208784T3 (da) * 2001-06-22 2013-03-18 Chugai Pharmaceutical Co Ltd Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
CN102702353A (zh) 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
SI1800693T1 (sl) * 2004-08-24 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Adjuvantna terapija z uporabo protitelesa proti glipikanu 3
ES2372537T3 (es) 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US8828666B2 (en) * 2007-06-18 2014-09-09 Chugai Seiyaku Kabushiki Kaisha Method for measuring bonding activity of antibody which mimics antibody-dependent cell medicated cytotoxic activity
WO2009012394A1 (en) * 2007-07-17 2009-01-22 Medarex, Inc. Monoclonal antibodies against glypican-3
HRP20141236T1 (hr) 2007-09-04 2015-02-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Office of Technology Transfer DELECIJE U DOMENI II PSEUDOMONAS EGZOTOKSINA „A“ KOJIMA SE SMANJUJE NESPECIFIČNA TOKSIČNOST
MY148637A (en) * 2007-09-28 2013-05-15 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
TW200949248A (en) * 2008-03-17 2009-12-01 Univ Miyazaki Method for detection of liver cancer cell using anti-glypican-3 antibody
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
WO2011032022A1 (en) 2009-09-11 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Improved pseudomonas exotoxin a with reduced immunogenicity
CN105968209B (zh) * 2011-04-19 2021-08-03 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途

Also Published As

Publication number Publication date
JP2015526387A (ja) 2015-09-10
CN104520331A (zh) 2015-04-15
WO2013181543A1 (en) 2013-12-05
JP2019062910A (ja) 2019-04-25
CN104520331B (zh) 2018-09-07
WO2013181543A8 (en) 2014-12-31
US9409994B2 (en) 2016-08-09
US20150147330A1 (en) 2015-05-28
KR102159773B1 (ko) 2020-09-28
SG11201407972RA (en) 2015-01-29
KR20150014521A (ko) 2015-02-06

Similar Documents

Publication Publication Date Title
JP6494507B2 (ja) グリピカン−３に対する高親和性モノクローナル抗体およびその使用
US10640571B2 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
JP6307085B2 (ja) メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
EP3327037B1 (en) Mesothelin domain-specific monoclonal antibodies and use thereof
HK1228931B (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HK1228931A1 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HK1213000B (en) Mesothelin antibodies and methods for eliciting potent antitumor activity
HK1219965B (en) Human monoclonal antibodies specific for glypican-3 and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180315

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190305

R150 Certificate of patent or registration of utility model

Ref document number: 6494507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250